
    
      This is an open-label single-arm study that will examine the antiviral efficacy, safety and
      tolerability of 12 weeks daily therapy with fixed dose combination (FDC) of SOF/VEL and
      SOF/VEL/VOX administered respectively in HCV-infected treatment-naïve adult participants and
      in HCV-infected individuals with a history of virologic failure to SOF/LDV or other
      DAA-containing regimen. A total of 100 participants will be enrolled in this portion of the
      SHARED study, labelled the "SHARED 3 study": 60 treatment-naïve participants and 40
      individuals with history of virologic failure to SOF/LDV or other DAA-containing regimen
    
  